Press Releases

Press Releases

Date Title and Summary Additional Formats
Toggle Summary Arena Pharmaceuticals Announces R&D Leadership Transition
Paul D. Streck , M.D., Appointed as Senior Vice President, Clinical Development and Chief Medical Officer, Bringing Successful Development and Launch Experience Across Multiple Therapeutic Indications SAN DIEGO --(BUSINESS WIRE)--Nov. 30, 2020-- Arena Pharmaceuticals, Inc.
View HTML
Toggle Summary Arena Pharmaceuticals to Present at the Evercore ISI HealthCONx Conference on December 1
SAN DIEGO , Nov. 24, 2020 /PRNewswire/ --  Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that Amit D. Munshi , the Company's President and Chief Executive Officer, is scheduled to participate in a virtual fireside chat at the 3rd Annual Evercore ISI HealthCONx Conference on Tuesday,
View HTML
Toggle Summary Arena Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO , Nov. 19, 2020 /PRNewswire/ --  Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that on November 15, 2020 , the Compensation Committee of its Board of Directors granted to 13 new employees inducement stock options to purchase an aggregate of 96,025 shares of its common stock
View HTML
Toggle Summary Arena Reports Third Quarter Financial Results with Strong Cash Position, Advancing Etrasimod Into a Phase 3 Registrational Program in Atopic Dermatitis
- Delivered compelling topline results from ADVISE Ph 2b trial evaluating etrasimod in atopic dermatitis; advancing into a Ph 3 registrational program   - Initiated etrasimod trials: ELEVATE UC 12 Ph 3, GLADIATOR UC and alopecia areata Ph 2   - Completed enrollment of CAPTIVATE Ph 2b trial
View HTML
Toggle Summary Arena Pharmaceuticals Advancing Etrasimod Into Phase 3 Program in Atopic Dermatitis (AD), Reports Compelling Topline Results from Phase 2b ADVISE Trial
- Etrasimod 2 mg in the primary analysis achieved statistical significance of the registrational endpoint vIGA at week 12   - Etrasimod 2 mg in the primary analysis demonstrated statistical significance in percent change in EASI, EASI-75, and pruritis at week 4   - Etrasimod did not meet the Ph 2b
View HTML
Toggle Summary Arena Pharmaceuticals to Release Third Quarter 2020 Financial Results and Provide Corporate Update on November 9
SAN DIEGO , Nov. 2, 2020 /PRNewswire/ --  Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) will release its third quarter 2020 financial results and provide a corporate update on Monday, November 9, 2020 , after the close of the U.S. financial markets. The Company will host a conference call and live
View HTML
Toggle Summary Arena Pharmaceuticals Announces Launch of Longboard Pharmaceuticals With $56M Financing, Building a Novel Neuroscience Drug Development Company
- Longboard Pharmaceuticals (formerly Arena Neuroscience) is an Arena-founded independent company focused on advancing promising investigational therapies for rare neurological diseases   - Longboard's investor syndicate includes Farallon Capital, Cormorant Asset Management, HBM Healthcare
View HTML
Toggle Summary Arena Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO , Oct. 20, 2020 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that on October 15, 2020 , the Compensation Committee of its Board of Directors granted to seven new employees inducement stock options to purchase an aggregate of 66,475 shares of its common stock
View HTML
Toggle Summary Arena Pharmaceuticals' Presence at United European Gastroenterology Week Strengthens Ongoing Commitment to the Gastrointestinal Disease Community
- New data from the Phase 2 OASIS trial and its open-label extension for etrasimod in ulcerative colitis   - Arena sponsored symposium: Opening the Door to Emerging Investigational Treatments in Ulcerative Colitis: What Awaits Us? SAN DIEGO , Oct. 9, 2020 /PRNewswire/ --  Arena Pharmaceuticals,
View HTML
Toggle Summary Arena Pharmaceuticals Completes Full Enrollment of Olorinab Phase 2 CAPTIVATE Trial for Abdominal Pain in Irritable Bowel Syndrome
- Evaluating 3 doses of olorinab in study participants with the clinical diagnosis of irritable bowel syndrome with predominant constipation (IBS-C) or diarrhea (IBS-D)   - Topline data expected Q1 2021   - Significant unmet need for non-opioid, peripherally acting pain management in
View HTML